Physician profile
Jack Son Kim
NPI 1679808356
$2,532.05
in general payments reported to CMS, 2019-2025
14 companies · $586 in 2025
The $586 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $268 · 2022: $764 · 2023: $524 · 2024: $390 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $774.26 | 2021-2023 | |
| Bausch & Lomb Americas INC. | $700.06 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $486.43 | 2022-2025 | Rocklatan, Eysuvis, Tryptyr |
| Aerie Pharmaceuticals, INC. | $155.21 | 2021 | |
| Oyster Point Pharma, INC. | $153.44 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $71.50 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $35.47 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $31.43 | 2025 | |
| Dompe US, INC. | $29.69 | 2024 | Oxervate |
| Amgen INC. | $24.01 | 2025 | Tepezza |
| Abbvie INC. | $23.13 | 2025 | |
| Eyevance Pharmaceuticals LLC | $18.66 | 2021 | |
| Harrow Eye, LLC | $15.65 | 2025 | Vevye |
| Thea Pharma INC. | $13.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.